Risk of underlying chronic medical conditions for invasive pneumococcal disease in adults

Vaccine ◽  
2016 ◽  
Vol 34 (36) ◽  
pp. 4293-4297 ◽  
Author(s):  
Roger Baxter ◽  
Arnold Yee ◽  
Laurie Aukes ◽  
Vincenza Snow ◽  
Bruce Fireman ◽  
...  
2013 ◽  
Vol 16 (3) ◽  
pp. A232
Author(s):  
D. Weycker ◽  
R. Farkouh ◽  
D.R. Strutton ◽  
J. Edelsberg ◽  
K. Shea ◽  
...  

2019 ◽  
Vol 70 (12) ◽  
pp. 2484-2492 ◽  
Author(s):  
Sana S Ahmed ◽  
Tracy Pondo ◽  
Wei Xing ◽  
Lesley McGee ◽  
Monica Farley ◽  
...  

Abstract Background The 13-valent pneumococcal vaccine (PCV13) was introduced for US children in 2010 and for immunocompromised adults ≥19 years old in series with the 23-valent polysaccharide vaccine (PPSV23) in 2012. We evaluated PCV13 indirect effects on invasive pneumococcal disease (IPD) among adults with and without PCV13 indications. Methods Using Active Bacterial Core surveillance and the National Health Survey, using Active Bacterial Core surveillance and the National Health Interview Survey, we estimated and compared IPD incidence in 2013–2014 and 2007–2008, by age and serotype group (PCV13, PPSV23-unique, or nonvaccine types [NVTs]), among adults with and without PCV13 indications. Results IPD incidence declined among all adults. Among adults 19–64 years, PCV13-type IPD declined 57% (95% confidence interval [CI], −68% to −43%) in adults with immunocompromising conditions (indication for PCV13 use), 57% (95% CI, −62% to –52%) in immunocompetent adults with chronic medical conditions (CMCs, indications for PPSV23 use alone), and 74% (95% CI, −78% to −70%) in adults with neither vaccine indication. Among adults aged ≥65 years, PCV13-type IPD decreased 68% (95% CI, −76% to −60%) in those with immunocompromising conditions, 68% (95% CI, −72% to −63%) in those with CMCs, and 71% (95% CI, −77% to −64%) in healthy adults. PPSV23-unique types increased in adults 19‒64 years with CMCs, and NVTs did not change among adults with or without PCV13 indications. From 2013 to 2014, non-PCV13 serotypes accounted for 80% of IPD. Conclusions IPD incidence among US adults declined after PCV13 introduction in children. Similar reductions in PCV13-type IPD in those with and without PCV13 indications suggest that observed benefits are largely due to indirect effects from pediatric PCV13 use rather than direct use among adults.


2014 ◽  
Vol 59 (5) ◽  
pp. 615-623 ◽  
Author(s):  
Stephen I. Pelton ◽  
Derek Weycker ◽  
Raymond A. Farkouh ◽  
David R. Strutton ◽  
Kimberly M. Shea ◽  
...  

2016 ◽  
Vol 16 (1) ◽  
Author(s):  
Derek Weycker ◽  
Raymond A. Farkouh ◽  
David R. Strutton ◽  
John Edelsberg ◽  
Kimberly M. Shea ◽  
...  

2014 ◽  
Vol 1 (1) ◽  
Author(s):  
Kimberly M. Shea ◽  
John Edelsberg ◽  
Derek Weycker ◽  
Raymond A. Farkouh ◽  
David R. Strutton ◽  
...  

Abstract Background.  Although it is widely accepted that adults with immunocompromising conditions are at greatly increased risk of pneumococcal infection, the extent of risk among immunocompetent adults with chronic medical conditions is less certain, particularly in the current era of universal vaccination of children with pneumococcal conjugate vaccines. Methods.  We conducted a retrospective cohort study using data from 3 healthcare claims repositories (2006–2010) to compare rates of pneumococcal disease in immunocompetent adults with chronic medical conditions (“at-risk”) and immunocompromised adults (“high-risk”), with rates in adults without these conditions (“healthy”). Risk profiles and episodes of pneumococcal disease—all-cause pneumonia, pneumococcal pneumonia, and invasive pneumococcal disease (IPD)—were ascertained from diagnosis, procedure, and drug codes. Results.  Rates of all-cause pneumonia among at-risk persons aged 18–49 years, 50–64 years, and ≥65 years were 3.2 (95% confidence interval [CI], 3.1–3.2), 3.1 (95% CI, 3.1–3.1), and 3.0 (95% CI, 3.0–3.0) times the rates in age-matched healthy counterparts, respectively. We idetified rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, and neuromuscular or seizure disorders as additional at-risk conditions for pneumococcal disease. Among persons with at-risk conditions, the rate of all-cause pneumonia substantially increased with the accumulation of concurrent at-risk conditions (risk stacking): among persons 18–49 years, rate ratios increased from 2.5 (95% CI, 2.5–2.5) in those with 1 at-risk condition to 6.2 (95% CI, 6.1–6.3) in those with 2 conditions, and to 15.6 (95% CI, 15.3–16.0) in those with ≥3 conditions. Findings for pneumococcal pneumonia and IPD were similar. Conclusions.  Despite widespread use of pneumococcal conjugate vaccines, rates of pneumonia and IPD remain disproportionately high in adults with at-risk conditions, including those with conditions not currently included in the Advisory Committee on Immunization Practices’ guidelines for prevention and those with multiple at-risk conditions.


Sign in / Sign up

Export Citation Format

Share Document